Biologic agent dupilumab effective in improving asthma exacerbations and lung function, study shows - Earth News Report
A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11. The findings of the international multicenter Liberty Asthma VOYAGE trial, reported
